CTLA4 and neoplasm: Immunotherapies usually target the immune checkpoint blockade (ICB) through the use of monoclonal antibodies against inhibitory signaling molecules expressed on tumor and immune cells, such as programmed death-1 (PD-1), PD-1 ligand (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA4).